Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizing agent presented as a 5% w/w cream for topical use. It is applied to areas of sun‑damaged skin to treat actinic keratosis, a precancerous lesion, in adult patients by enabling targeted photodynamic therapy that selectively destroys dysplastic cells.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and logistics for this EU‑approved photodynamic therapy product to meet clinical demand.

Metvix is employed in photodynamic therapy for actinic keratosis, a field cancerization of sun‑damaged skin that can progress to squamous cell carcinoma, providing a non‑surgical option for lesion clearance. - Actinic keratosis (multiple lesions): reduces the number of visible lesions across the treated area. - Actinic keratosis (individual lesions): achieves complete clinical clearance of targeted lesions. - Field cancerization of sun‑damaged skin: treats subclinical dysplastic cells to prevent future lesion development. - Prevention of new actinic lesions: diminishes emergence of new lesions in treated area over several months.

Methyl aminolevulinate cream may cause local and systemic reactions after application and light activation.

Common Side Effects: - Application site pain: mild to moderate discomfort during illumination. - Erythema: redness of the treated skin. - Edema: swelling around the application area. - Scaling or crusting: skin flaking as lesions resolve.

Serious or Rare Side Effects: - Severe phototoxic reaction: intense pain, blistering, or ulceration requiring medical attention. - Infection: secondary bacterial infection of treated sites. - Allergic contact dermatitis: widespread rash or swelling. - Ulceration: deep tissue damage that may lead to scarring.

When using Metvix, careful patient management and site care are essential. - Patient selection: use in adults with diagnosed actinic keratosis. - Sun exposure: avoid direct sunlight on treated area for at least 48 hours after illumination. - Concurrent photosensitizers: discontinue systemic photosensitizing drugs such as tetracyclines during treatment. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Application site care: keep area clean and avoid trauma during healing. - Store below 25°C: keep in original packaging, protect from moisture and light.

Methyl aminolevulinate may interact with other agents that affect photosensitivity or wound healing.

Major Interactions (Avoid): - Systemic photosensitizing agents (e.g., tetracyclines, retinoids): may increase phototoxicity. - Topical irritants (e.g., benzoyl peroxide, salicylic acid) applied to same area: may exacerbate skin reactions.

Moderate Interactions (Monitor Closely): - Topical corticosteroids applied after treatment: may reduce efficacy of photodynamic effect. - Oral anticoagulants: monitor for bleeding if ulceration occurs. - Immunosuppressive therapy: may diminish treatment response.